Kinglion Benzylpenicillin Sodium Injection

KINGLION BENZYLPENICILLIN SODIUM INJECTION 1M

Composition, Pharmacological properties, Mechanism of action, Therapeutic indications, Undesirable effects, Precaution for use, Contraindications, Routes of administration, Dosage and method of administration, Storage, Shelf life, Marketer and Manufacturer of Kinglion Benzyl penicillin Injection Medicine for Infections.

 

COMPOSITION

Each vial contains benzylpenicillin BP 1,000,000 UI (1 mega)

Excipients: none

 

PHARMACOLOGICAL PROPERTIES

ANTIBIOTIC: Antibacterial spectrum is that of penicillin G

Species usually sensitive:

Streptococci, Corynebacterium diptheriae, Listeria monocytogenes, Bacillus anthracis, Streptobacillus moniliformis, Erysipelothrix rhisopathiae, Neisseria meningitidis, Pasteurella multocida, Moraxella.

Peptostreptococcus, Clostridium sp, Propionibacterium acnes.

Actinomyces isreali, Fusobacterium sp.

Treponema, Borrelia, Leptospira sp.

 

Species moderately sensitive:

Enterococcus faecalis.

 

Resistant Species:

Staphylococci, Gram-negative bacili: enterobacteria, non-fermenting strict aerobes, Moraxella catarrhalis, Bacteriodes sp.

Mycobacterla, mycoplasmas, chlamydiae, Legionella sp, rickettsiae.

 

Species sometimes sensitive:

Percentage of acquired resistance variable; hence susceptibility cannot be predicted in the absence of an antibiogram: Streptococcus pneumoniae, Neisseria gonorrhoeae, Haemophilus influenza, E. faecium, prevotella.

 

MECHANISMS OF ACTION

Inhibition of the process of transpeptidation that binds peptidoglycans of the bacterial cell wall.

Beta-lactams bind also inactivate the target enzymes present on the inner surface of the bacterial cell membrane:

penicillin-binding proteins: transpeptidases, carboxypeptidases, endopeptidases.

Inactivation of proteins PBP, A, IBS, 2 AND 3 causes cell death.

Beta-lactams also inactivate the endogenous inhibitors of bacterial autolysis. Destroyed by penicillinase.

Resistance is enzymatic extrachromosomic, intrinsic, slow at multiple levels.

 

THERAPEUTIC INDICATIONS

Infections due to penicillin-susceptible organisms: pneumonia, tonsillitis, anthrax, septicaemia, menigitis.

 

UNDESIRABLE EFFECTS

A generalized hypersensitivity reaction may develop one to three weeks after the start of treatment, with urticaria, fever eosinophilia, joint pain, angioneurotic oedema, erythema multiforme and exfoliative dermatitis, whilst a rapid urticarial reaction can develop within a few hours.

NEUTROPENIA: when high doses greater than 12 grams per day are used in the treatment of endocarditis. Requires hematological monitoring.

 

PRECAUTIONS FOR USE

ASTHMA, ALLERGIC DIATHESIS

ALLERGY TO CEPHALOSPORINS, of the first and second generation, risk weaker with the third generation. ALLERGY TO AN AMINOPENICILLIN

RENAL IMPAIRMENT: reduce the dose.

 

CONTRA-INDICATIONS

ALLERGY TO PENICILLIN G

INTRATHECAL ROUTE

LACTATION
Drug passes into breast milk; prescribe with caution due to the risk of allergic reactions.

INDUCED LUPUS

 

ROUTES OF ADMINISTRATION

1- INTRAMUSCULAR

2- INTRAVENOUS (AS INFUSION)

 

DOSAGE AND METHOD OF ADMINISTRATION

Usual doses given by intramuscular injection or intravenous infusion:

-Adults: 1 to 3 million units/day in 4 divided doses. (maximum 10 to 20 M IU/day)

-Children: 80,000 IU/kg/day in 4 divided doses (maximum 400,000 IU/kg/day)

Treatment must be stopped immediately if any allergic manifestation occurs and injectable corticoids and/or antihistamines given if necessary.

In severe forms, the patient must be admitted to intensive care, with assisted ventilation, cardiac massage and fluid replacement under monitoring of venous pressure.

If necessary, take account of the risk of sodium overload: sodium content:
38.7 mg per 1 million units.

 

STORAGE

Store in the original package in order to protect from moisture. Do not store above 25°C. Keep out of the reach and sight of children. Any unused product must be discarded.

 

SHELF LIFE

Three years when stored as prescribed.

NAFDAC REG, NO: B4-3470

 

MARKETED BY

SOOTHE HEALTHCARE & INVESTMENT LTD.

385, IKORODU ROAD, OJOTA, LAGOS, NIGERIA

 

Manufactured by

North China Pharmaceutical Co. Ltd.,

NO. 388, Heping East Road,

Shijiazhuang, Hebei, China.

Advertisements